These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33423348)

  • 1. The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
    Zhang Y; Xu W; Zhu X; Li X; Li J; Shu X; Lai J; Xie J; Xie C; Peng L
    J Viral Hepat; 2021 Apr; 28(4):592-600. PubMed ID: 33423348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
    Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
    BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
    Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
    Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
    Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
    Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ
    PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
    Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Wu XN; Yang JH
    J Clin Gastroenterol; 2019 Apr; 53(4):e171-e177. PubMed ID: 29659382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
    Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
    Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
    J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
    Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
    Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
    Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
    Nguyen MH; Atsukawa M; Ishikawa T; Yasuda S; Yokohama K; Trinh HN; Arai T; Fukunishi S; Ogawa E; Hsu YC; Maeda M; Dang H; Tseng CH; Takahashi H; Jun DW; Watanabe T; Chuma M; Nozaki A; Kawada N; Cheung R; Enomoto M; Takaguchi K; Toyoda H
    Am J Gastroenterol; 2021 Jun; 116(6):1264-1273. PubMed ID: 34074829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
    Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
    Cheng CH; Hung HC; Lee JC; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Chan KM; Lee WC
    Ann Transplant; 2023 Apr; 28():e938731. PubMed ID: 37081752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
    Sato K; Inoue J; Akahane T; Kobayashi T; Sato S; Kisara N; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Masamune A
    Medicine (Baltimore); 2022 Sep; 101(39):e30630. PubMed ID: 36181074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.
    Jung CY; Kim HW; Ahn SH; Kim SU; Kim BS
    Liver Int; 2022 May; 42(5):1017-1026. PubMed ID: 35220649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
    Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA
    J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.